# MGMT

## Overview
The MGMT gene encodes the protein O-6-methylguanine-DNA methyltransferase, a critical DNA repair enzyme that plays a pivotal role in maintaining genomic integrity by removing alkyl groups from the O6 position of guanine. This protein is categorized as a DNA repair enzyme and is essential for preventing mutations that could lead to cancer. The MGMT protein operates through a "suicide" repair mechanism, where it transfers the alkyl group to a cysteine residue within its active site, resulting in its own inactivation and subsequent degradation (Bugni2007Genetic). The regulation of MGMT is tightly controlled by epigenetic mechanisms, such as promoter methylation, which modulate its expression and activity in response to cellular needs (Watts1997Methylation). Clinically, MGMT is significant in cancer treatment, particularly in glioblastoma, where its expression levels can influence the effectiveness of alkylating chemotherapeutic agents (Hegi2004Clinical; Esteller2000Inactivation). The gene's role as a biomarker and therapeutic target underscores its importance in oncology (Gerson2002Clinical; Hegi2008Correlation).

## Structure
The human MGMT (O6-methylguanine-DNA methyltransferase) protein is a DNA repair enzyme that plays a crucial role in removing alkyl groups from the O6 position of guanine. The primary structure of MGMT consists of a single polypeptide chain, with a significant cysteine residue at position 145 serving as the alkyl-acceptor site, which is essential for its repair function (Tano1990Isolation). The secondary structure of MGMT includes alpha-helices and beta-sheets, contributing to its stability and function (Gharouni2021In). 

The tertiary structure of MGMT is stabilized by a zinc ion, which bridges the N-terminal and C-terminal domains, enhancing the protein's stability and structural integrity (Gharouni2021In). The N-terminal domain comprises three-stranded anti-parallel β-sheets and helices, while the C-terminal domain contains additional β-sheets, α-helices, and a DNA-binding motif (Gharouni2021In). MGMT functions as a monomer and lacks a quaternary structure. 

Post-translational modifications of MGMT include ubiquitination, which targets the protein for degradation, regulating its cellular levels and activity. These structural features are critical for MGMT's role in DNA repair and its interaction with chemotherapeutic drugs (Gharouni2021In).

## Function
The MGMT (O6-methylguanine-DNA methyltransferase) protein plays a crucial role in DNA repair by removing alkyl groups from the O6 position of guanine, a process essential for maintaining genomic stability and preventing mutations that could lead to cancer (Fang2024The). This repair mechanism is often referred to as a "suicide" repair process because MGMT transfers the alkyl group to a cysteine residue within its active site, leading to its own inactivation and subsequent degradation (Bugni2007Genetic). 

MGMT is active in the cell nucleus, where it directly repairs DNA damage caused by alkylating agents, thus protecting cells from their mutagenic and cytotoxic effects (Fang2024The). The protein's activity is crucial for preventing GC to AT mutations and reducing cytotoxicity, which are critical in cancer prevention (Fang2024The). 

In healthy human cells, MGMT's function is tightly regulated, with its expression being modulated by epigenetic mechanisms such as promoter methylation. This regulation ensures that MGMT is available to repair DNA damage efficiently, thereby maintaining cellular and organismal health (Watts1997Methylation). The protein's interactions with other cellular components, such as PCNA and p21, further influence its activity and stability, particularly during the cell cycle (Mostofa2018Sphase).

## Clinical Significance
The MGMT gene, encoding the enzyme O-6-methylguanine-DNA methyltransferase, plays a significant role in the clinical response to alkylating agents used in cancer treatment, particularly in glioblastoma. Alterations in MGMT expression, such as promoter methylation, are associated with increased sensitivity to these agents. Methylation of the MGMT promoter silences the gene, reducing its expression and allowing alkylating agents to form lethal DNA cross-links, which enhances tumor cell death. This epigenetic alteration is linked to improved survival outcomes in glioblastoma patients treated with temozolomide and other alkylating agents (Hegi2004Clinical; Esteller2000Inactivation).

Conversely, overexpression of MGMT is associated with resistance to alkylating chemotherapy. In glioblastoma, increased MGMT expression, often due to histone modifications rather than promoter methylation changes, contributes to resistance against temozolomide. This resistance can be mitigated by using MGMT inhibitors like O6-benzylguanine, which restore sensitivity to the drug (Kitange2012Inhibition).

The clinical significance of MGMT extends to its potential as a biomarker for predicting treatment response and as a target for therapeutic strategies aimed at modulating drug resistance in cancer (Gerson2002Clinical; Hegi2008Correlation).

## Interactions
The human O6-methylguanine-DNA methyltransferase (MGMT) protein is involved in several interactions with other proteins, influencing its function and regulation. MGMT interacts with the E6 oncoprotein from human papillomavirus (HPV), which promotes its degradation through the ubiquitin-proteasome pathway. This process is mediated by the E6-associated protein (E6-AP), which facilitates the ubiquitination of MGMT, leading to its proteasomal degradation (Srivenugopal2002The).

MGMT also interacts with proliferating cell nuclear antigen (PCNA) through a PCNA-interacting protein (PIP) box motif. This interaction is crucial for the regulation of MGMT during the S-phase of the cell cycle, where it is targeted for ubiquitination and degradation by the CRL4 Cdt2 ubiquitin ligase. The presence of p21Cip1 can disrupt the MGMT-PCNA interaction, reducing the amount of PCNA-associated MGMT and influencing its stability and function (Mostofa2018Sphase).

These interactions highlight the role of MGMT in DNA repair and its regulation by other proteins, which can affect its activity and stability in response to cellular conditions and DNA damage (Mostofa2018Sphase).


## References


[1. (Hegi2004Clinical) Monika E. Hegi, Annie-Claire Diserens, Sophie Godard, Pierre-Yves Dietrich, Luca Regli, Sandrine Ostermann, Philippe Otten, Guy Van Melle, Nicolas de Tribolet, and Roger Stupp. Clinical trial substantiates the predictive value of o-6-methylguanine-dna methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Research, 10(6):1871–1874, March 2004. URL: http://dx.doi.org/10.1158/1078-0432.ccr-03-0384, doi:10.1158/1078-0432.ccr-03-0384. This article has 627 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-03-0384)

[2. (Mostofa2018Sphase) AGM Mostofa, Surendra R. Punganuru, Hanumantha Rao Madala, and Kalkunte S. Srivenugopal. S-phase specific downregulation of human o6-methylguanine dna methyltransferase (mgmt) and its serendipitous interactions with pcna and p21cip1 proteins in glioma cells. Neoplasia, 20(4):305–323, April 2018. URL: http://dx.doi.org/10.1016/j.neo.2018.01.010, doi:10.1016/j.neo.2018.01.010. This article has 24 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.neo.2018.01.010)

[3. (Tano1990Isolation) K Tano, S Shiota, J Collier, R S Foote, and S Mitra. Isolation and structural characterization of a cdna clone encoding the human dna repair protein for o6-alkylguanine. Proceedings of the National Academy of Sciences, 87(2):686–690, January 1990. URL: http://dx.doi.org/10.1073/pnas.87.2.686, doi:10.1073/pnas.87.2.686. This article has 167 citations.](https://doi.org/10.1073/pnas.87.2.686)

[4. (Kitange2012Inhibition) Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jenny L. Pokorny, Ling Cen, Paul A. Decker, Wenting Wu, Gwen A. Lomberk, Shiv K. Gupta, Raul A. Urrutia, and Jann N. Sarkaria. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to mgmt upregulation in glioblastoma xenografts. Clinical Cancer Research, 18(15):4070–4079, July 2012. URL: http://dx.doi.org/10.1158/1078-0432.ccr-12-0560, doi:10.1158/1078-0432.ccr-12-0560. This article has 158 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-12-0560)

[5. (Hegi2008Correlation) Monika E. Hegi, Lili Liu, James G. Herman, Roger Stupp, Wolfgang Wick, Michael Weller, Minesh P. Mehta, and Mark R. Gilbert. Correlation of o6-methylguanine methyltransferase (mgmt) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate mgmt activity. Journal of Clinical Oncology, 26(25):4189–4199, September 2008. URL: http://dx.doi.org/10.1200/jco.2007.11.5964, doi:10.1200/jco.2007.11.5964. This article has 637 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1200/jco.2007.11.5964)

[6. (Fang2024The) Qingming Fang. The versatile attributes of mgmt: its repair mechanism, crosstalk with other dna repair pathways, and its role in cancer. Cancers, 16(2):331, January 2024. URL: http://dx.doi.org/10.3390/cancers16020331, doi:10.3390/cancers16020331. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers16020331)

[7. (Watts1997Methylation) George S. Watts, Russell O. Pieper, Joseph F. Costello, Yei-Mei Peng, William S. Dalton, and Bernard W. Futscher. Methylation of discrete regions of the o6-methylguanine dna methyltransferase (mgmt) cpg island is associated with heterochromatinization of the mgmt transcription start site and silencing of the gene. Molecular and Cellular Biology, 17(9):5612–5619, September 1997. URL: http://dx.doi.org/10.1128/mcb.17.9.5612, doi:10.1128/mcb.17.9.5612. This article has 166 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.17.9.5612)

[8. (Esteller2000Inactivation) Manel Esteller, Jesus Garcia-Foncillas, Esther Andion, Steven N. Goodman, Oscar F. Hidalgo, Vicente Vanaclocha, Stephen B. Baylin, and James G. Herman. Inactivation of the dna-repair genemgmtand the clinical response of gliomas to alkylating agents. New England Journal of Medicine, 343(19):1350–1354, November 2000. URL: http://dx.doi.org/10.1056/nejm200011093431901, doi:10.1056/nejm200011093431901. This article has 1730 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1056/nejm200011093431901)

[9. (Bugni2007Genetic) James M. Bugni, Jiali Han, Miaw-sheue Tsai, David J. Hunter, and Leona D. Samson. Genetic association and functional studies of major polymorphic variants of mgmt. DNA Repair, 6(8):1116–1126, August 2007. URL: http://dx.doi.org/10.1016/j.dnarep.2007.03.023, doi:10.1016/j.dnarep.2007.03.023. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.dnarep.2007.03.023)

[10. (Srivenugopal2002The) Kalkunte S Srivenugopal and Francis Ali-Osman. The dna repair protein, o6-methylguanine-dna methyltransferase is a proteolytic target for the e6 human papillomavirus oncoprotein. Oncogene, 21(38):5940–5945, August 2002. URL: http://dx.doi.org/10.1038/sj.onc.1205762, doi:10.1038/sj.onc.1205762. This article has 62 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1205762)

[11. (Gerson2002Clinical) Stanton L. Gerson. Clinical relevance of mgmt in the treatment of cancer. Journal of Clinical Oncology, 20(9):2388–2399, May 2002. URL: http://dx.doi.org/10.1200/jco.2002.06.110, doi:10.1200/jco.2002.06.110. This article has 338 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1200/jco.2002.06.110)

[12. (Gharouni2021In) Marzieh Gharouni, Hamid Mosaddeghi, Jamshid Mehrzad, Ali Es-haghi, and Alireza Motavalizadehkakhky. In silico profiling and structural insights of zinc metal ion on o6-methylguanine methyl transferase and its interactions using molecular dynamics approach. Journal of Molecular Modeling, January 2021. URL: http://dx.doi.org/10.1007/s00894-020-04631-x, doi:10.1007/s00894-020-04631-x. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00894-020-04631-x)